Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 160

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 160
---
 therefrom, taking into account certain considerations 
 stated in the Companies Law. See “Management—Board Practices—Approval of Related Party Transactions under Israeli                          
 Law” for additional information.                                                                                                           |

| ● | Shareholder approval. We                                                                                                                        
 will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather            
 than seeking approval for corporation actions in accordance with NYSE American rules. In particular, under NYSE American 713, shareholder       
 approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20%                    
 or more of the acquirer’s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest                    
 in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment 
 of equity compensation arrangements (although under the provisions of the Companies Law there is no requirement for shareholder approval        
 for the adoption/amendment of the equity compensation plan); and (iv) issuances of 20% or more of the shares or voting rights                   
 (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales               
 by directors/officers/5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares.           
 By contrast, under the Companies Law, shareholder approval is required for, among other things: (i) arrangements with directors                 
 and with chief executive officer concerning the terms of their service or indemnification, exemption and insurance for their service            
 (or for any other position that they may hold at a company), for which approvals of the compensation committee, board of directors              
 and shareholders are all required, (ii) extraordinary transactions with controlling shareholders of publicly held companies,                    
 which require the special approval, (iii) terms of employment or other engagement of the controlling shareholder of us or such                  
 controlling shareholder’s relative, which require special approval and (iv) issuances of 20% or more of the shares or voting                    
 rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via              
 sales by directors/officers/5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value                
 of shares. In addition, under the Companies Law, a merger requires approval